Add To Watchlist
Share URL
About The Company
Description
International Biotechnology Trust plc specializes in investments in development stage and late stage companies.
Read More
Overview
Value
23
Growth
2
Health
62
Management
35
Analyst Opinion
80
Total
40
All Scores Out Of 100
Best Features
- Earnings growth has improved recently
- Has a low level of debt
- Has strong financial health
- Price-to-earnings ratio of 5.2 is lower than the market average (19.6x)
- Liked by analysts
- Has strong dividend growth
- Low preportion of income is paid as dividend
Risk Factors
- Income is not covering expenditure and investment
- Earnings are negative
- There is a history of diluting shareholders
- No margin of safety at their current market price
- Poor earnings and cashflow growth
Market Peers
IBT.L
Key Figures
PE Ratio (TTM)
5.25
Margin Of Safety (DCF)
-98.66%
Revenue Growth (5 Year Average)
N/A
Ratings Consensus
Buy
Share Buybacks
-2.27%
Dividend Yeild (TTM)
0.03%
Valuation
Value Score
23
Desired Margin Of Safety
0%
▼
Tip: Set your desired Margin Of Safety
Free Cash Flow Type
Annual Cashflow Growth
0%
Discount Rate
0%
Buy Target: < 0.1 GBp ✘
Current Price: 740.5 GBp
Negative Cashflows: Cashflow can become negative due to operating losses, investing activities or financing activites. Negative cashflow makes it dificult to use a discounted free cashflow model to assess intrinsic value.
How Does This Work?
Show Advanced Options
This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.
Price/Earnings
5.25x
Free Cashflow Yeild
-0.03%
PE/Earnings Growth
N/A
Price/Book
10595.82x
Growth
Growth Score
2
- ✔ Revenue growth has improved this yeara
- ✔ Earnings growth has improved this year
- ✔ Free Cashflow growth has improved this year
- ✘ 5 Year Average Revenue growth of N/A is lower than the market average (10.97%)
- ✘ 5 Year Average Earnings growth of N/A is lower than the market average (14.48%)
- ✘ 5 Year Average Free Cashflow growth of -22.43% is lower than the market average (12.35%)
Revenue Growth
N/A
Earnings Growth
N/A
Cashflow Growth
-22.43%
Health
Health Score
62
Altman Z Score
N/A
Piostroski Score
N/A
Debt/Equity
0.14x
Current Assets/Liabilities
11.15x
Free Cashflow/Total Debt
0.03x
Debt/Capital
3.00x
Dividend
Secure Dividend Score
48
- ✘ At risk of being unsafe
- ✔ Long term dividend payout ratio of -1.54% is considered good
- ✔ Payout ratio (TTM) of 17.87% is lower than the average (40%)
- ✔ Dividends have shown growth over the last 5 years
- ✘ Dividend yeild of 0.03% is less than the market average (1.85%)
- ✘ Spending a higher percentage of their income on dividends than last 5 years
Dividend Yeild
0.03%
Dividend Growth
11.37%
Payout Ratio (Earnings)
17.87%
Payout Ratio (Cashflow)
-99.95%
Management
Management Score
35
Average Buybacks/Dilution
-2.27%
Recent Buybacks/Dilution
N/A
5 Year Price Volitility
11.84%
Return On Assets
-682.33%
Return On Capital Employed
-6.63%
Return On Equity
-782.99%
Return On Free Cashflow
15348.86%
Return On Investments
N/A
Analysts
Analyst Opinion
80
- ✔ Ratings consensus is Buy
SEC Filings
Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.
Other Information
Company Name
International Biotechnology Trust plc
Currency
GBp
Beta
0.286274
Vol Avg
43273
Ceo
Cik
Cusip
G4809R108
Exchange
London Stock Exchange
Full Time Employees
0
Industry
Asset Management
Sector
Financial Services
Ipo Date
1996-02-22
Address
10 Harewood Avenue
City
LONDON
State
Country
GB
Zip
WC2B 6ST
Phone
4402074217070
All financial data provided by FMP